Comment on

• Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.

  Fleischmann R, Connolly SE, Maldonado MA, Schiff M. Fleischmann R, et al. Arthritis Rheumatol. 2016 Sep;68(9):2083-9. doi: 10.1002/art.39714. Arthritis Rheumatol. 2016. PMID: 27111089 Free PMC article. Clinical Trial.
• Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al.

  Curtis JR, Wright GC, Strand V, Davis CS, Hitraya E, Sasso EH. Curtis JR, et al. Arthritis Rheumatol. 2017 Apr;69(4):863-865. doi: 10.1002/art.39981. Epub 2017 Mar 3. Arthritis Rheumatol. 2017. PMID: 27813312 Free PMC article. No abstract available.
• Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et al and Accompanying Editorial by Davis.

  Pincus T, Block JA, Yazici Y, Bergman MJ, Sokka T. Pincus T, et al. Arthritis Rheumatol. 2017 Apr;69(4):866-867. doi: 10.1002/art.40022. Epub 2017 Mar 3. Arthritis Rheumatol. 2017. PMID: 27992686 No abstract available.